Alcidion Group Valuation

Is ALC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALC (A$0.06) is trading below our estimate of fair value (A$0.18)

Significantly Below Fair Value: ALC is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALC?

Key metric: As ALC is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALC. This is calculated by dividing ALC's market cap by their current revenue.
What is ALC's PS Ratio?
PS Ratio2.2x
SalesAU$37.06m
Market CapAU$80.58m

Price to Sales Ratio vs Peers

How does ALC's PS Ratio compare to its peers?

The above table shows the PS ratio for ALC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average16x
M7T Mach7 Technologies
2.7x18.1%AU$79.6m
BMT Beamtree Holdings
2.9x21.9%AU$76.8m
MDR MedAdvisor
1.2x13.4%AU$157.1m
SHG Singular Health Group
57.1xn/aAU$53.3m
ALC Alcidion Group
2.2x8.2%AU$80.6m

Price-To-Sales vs Peers: ALC is good value based on its Price-To-Sales Ratio (2.2x) compared to the peer average (16x).


Price to Sales Ratio vs Industry

How does ALC's PS Ratio compare vs other companies in the AU Healthcare Services Industry?

7 CompaniesPrice / SalesEstimated GrowthMarket Cap
MDR MedAdvisor
1.2x13.4%US$97.83m
DOC Doctor Care Anywhere Group
0.3x6.3%US$15.99m
IME ImExHS
0.7x20.5%US$9.94m
VFX Visionflex Group
1.3xn/aUS$5.45m
ALC 2.2xIndustry Avg. 3.4xNo. of Companies7PS0816243240+
7 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALC is good value based on its Price-To-Sales Ratio (2.2x) compared to the Global Healthcare Services industry average (3.4x).


Price to Sales Ratio vs Fair Ratio

What is ALC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio2.2x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: ALC is good value based on its Price-To-Sales Ratio (2.2x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ALC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$0.06
AU$0.083
+38.9%
11.3%AU$0.09AU$0.07n/a3
Dec ’25AU$0.063
AU$0.083
+32.3%
11.3%AU$0.09AU$0.07n/a3
Nov ’25AU$0.053
AU$0.083
+57.2%
11.3%AU$0.09AU$0.07n/a3
Oct ’25AU$0.06
AU$0.083
+38.9%
11.3%AU$0.09AU$0.07n/a3
Sep ’25AU$0.072
AU$0.087
+20.4%
5.4%AU$0.09AU$0.08n/a3
Aug ’25AU$0.073
AU$0.093
+27.8%
10.1%AU$0.10AU$0.08n/a3
Jul ’25AU$0.051
AU$0.08
+56.9%
27.0%AU$0.10AU$0.05n/a3
Jun ’25AU$0.058
AU$0.08
+37.9%
27.0%AU$0.10AU$0.05n/a3
May ’25AU$0.052
AU$0.08
+53.8%
27.0%AU$0.10AU$0.05n/a3
Apr ’25AU$0.051
AU$0.077
+50.3%
26.8%AU$0.10AU$0.05n/a3
Mar ’25AU$0.046
AU$0.087
+88.4%
10.9%AU$0.10AU$0.08n/a3
Feb ’25AU$0.052
AU$0.097
+85.9%
12.9%AU$0.11AU$0.08n/a3
Jan ’25AU$0.075
AU$0.11
+46.7%
19.6%AU$0.13AU$0.08n/a3
Dec ’24AU$0.074
AU$0.11
+48.6%
19.6%AU$0.13AU$0.08AU$0.0633
Nov ’24AU$0.07
AU$0.14
+95.2%
12.4%AU$0.16AU$0.12AU$0.0533
Aug ’24AU$0.13
AU$0.16
+30.7%
7.6%AU$0.18AU$0.15AU$0.0733
Jul ’24AU$0.095
AU$0.19
+100.0%
5.3%AU$0.20AU$0.18AU$0.0512
Jun ’24AU$0.094
AU$0.19
+102.1%
5.3%AU$0.20AU$0.18AU$0.0582
May ’24AU$0.097
AU$0.19
+95.9%
5.3%AU$0.20AU$0.18AU$0.0522
Feb ’24AU$0.15
AU$0.20
+36.7%
2.4%AU$0.21AU$0.20AU$0.0522
Jan ’24AU$0.14
AU$0.20
+41.4%
2.4%AU$0.21AU$0.20AU$0.0752
Dec ’23AU$0.17
AU$0.20
+14.7%
2.6%AU$0.20AU$0.19AU$0.0742

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 14:48
End of Day Share Price 2024/12/19 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Alcidion Group Limited is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Elyse ShapiroBell Potter
Thomas WakimBell Potter
Elyse ShapiroCanaccord Genuity